Literature DB >> 30970263

High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions.

Marsilius Mues1, Laila Karra1, Damia Romero-Moya1, Anica Wandler2, Matthew J Hangauer3, Olga Ksionda1, Yvonne Thus1, Marthe Lindenbergh1, Kevin Shannon2, Michael T McManus3, Jeroen P Roose4.   

Abstract

Deregulated signal transduction is a cancer hallmark, and its complexity and interconnectivity imply that combination therapy should be considered, but large data volumes that cover the complexity are required in user-friendly ways. Here, we present a searchable database resource of synthetic lethality with a PI3 kinase signal transduction inhibitor by performing a saturation screen with an ultra-complex shRNA library containing 30 independent shRNAs per gene target. We focus on Ras-PI3 kinase signaling with T cell leukemia as a screening platform for multiple clinical and experimental reasons. Our resource predicts multiple combination-based therapies with high fidelity, ten of which we confirmed with small molecule inhibitors. Included are biochemical assays, as well as the IPI145 (duvelisib) inhibitor. We uncover the mechanism of synergy between the PI3 kinase inhibitor GDC0941 (pictilisib) and the tubulin inhibitor vincristine and demonstrate broad synergy in 28 cell lines of 5 cancer types and efficacy in preclinical leukemia mouse trials.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GDC0941; PI3 kinase; cancer; inhibitors; leukemia; preclinical mouse trials; screen; shRNA; signaling pathways; synthetic lethality; vincristine

Mesh:

Substances:

Year:  2019        PMID: 30970263      PMCID: PMC6690758          DOI: 10.1016/j.celrep.2019.03.045

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  87 in total

Review 1.  Treatment of acute lymphoblastic leukemia.

Authors:  Ching-Hon Pui; William E Evans
Journal:  N Engl J Med       Date:  2006-01-12       Impact factor: 91.245

2.  Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia.

Authors:  R J Aur; J Simone; H O Hustu; T Walters; L Borella; C Pratt; D Pinkel
Journal:  Blood       Date:  1971-03       Impact factor: 22.113

Review 3.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.

Authors:  Lauren M Thorpe; Haluk Yuzugullu; Jean J Zhao
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

Review 4.  Integrating genetic approaches into the discovery of anticancer drugs.

Authors:  L H Hartwell; P Szankasi; C J Roberts; A W Murray; S H Friend
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

5.  Targeting nonclassical oncogenes for therapy in T-ALL.

Authors:  Prem S Subramaniam; Dosh W Whye; Evgeni Efimenko; Jianchung Chen; Valeria Tosello; Kim De Keersmaecker; Adam Kashishian; Mary Ann Thompson; Mireia Castillo; Carlos Cordon-Cardo; Utpal P Davé; Adolfo Ferrando; Brian J Lannutti; Thomas G Diacovo
Journal:  Cancer Cell       Date:  2012-04-17       Impact factor: 31.743

Review 6.  RAS oncogenes: weaving a tumorigenic web.

Authors:  Yuliya Pylayeva-Gupta; Elda Grabocka; Dafna Bar-Sagi
Journal:  Nat Rev Cancer       Date:  2011-10-13       Impact factor: 60.716

Review 7.  The phosphoinositide 3-kinase pathway and therapy resistance in cancer.

Authors:  Kristin K Brown; Alex Toker
Journal:  F1000Prime Rep       Date:  2015-02-03

8.  Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.

Authors:  Olga Ksionda; Marsilius Mues; Anica M Wandler; Lisa Donker; Milou Tenhagen; Jesse Jun; Gregory S Ducker; Ksenia Matlawska-Wasowska; Kevin Shannon; Kevan M Shokat; Jeroen P Roose
Journal:  PLoS One       Date:  2018-05-25       Impact factor: 3.240

9.  Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.

Authors:  Jennifer O Lauchle; Doris Kim; Doan T Le; Keiko Akagi; Michael Crone; Kimberly Krisman; Kegan Warner; Jeannette M Bonifas; Qing Li; Kristen M Coakley; Ernesto Diaz-Flores; Matthew Gorman; Sally Przybranowski; Mary Tran; Scott C Kogan; Jeroen P Roose; Neal G Copeland; Nancy A Jenkins; Luis Parada; Linda Wolff; Judith Sebolt-Leopold; Kevin Shannon
Journal:  Nature       Date:  2009-09-02       Impact factor: 49.962

10.  PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.

Authors:  R L Ross; H R McPherson; L Kettlewell; S D Shnyder; C D Hurst; O Alder; M A Knowles
Journal:  BMC Cancer       Date:  2016-07-28       Impact factor: 4.430

View more
  1 in total

1.  Protocol for Comprehensive Synthetic Lethality Screens.

Authors:  Damia Romero-Moya; Jeroen P Roose
Journal:  STAR Protoc       Date:  2020-06-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.